Evidence map›Paper›PMID 33785036›Full record

ArticleJournal of hematology & oncology2021

Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice.

Keiji Minakawa, Tetsuro Yokokawa, Koki Ueda, Osamu Nakajima, Tomofumi Misaka, Yusuke Kimishima, Kento Wada, Yusuke Tomita, Saori Miura, Yuka Sato and 9 more

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology & oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Pulmonary Hypertension in Myeloproliferative Neoplasms: New Insights and Unexplored Horizons.American journal of respiratory and critical care medicine · 2023
    Article
  7. Article
  8. [Efficacy and safety of peginterferon-α2b for treatment of myeloproliterative neoplasms].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Keiji Minakawa *Department of Blood Transfusion and Transplantation Immunology, School of Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Tetsuro Yokokawa *Department of Cardiovascular Medicine, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Koki UedaDepartment of Blood Transfusion and Transplantation Immunology, School of Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Osamu NakajimaCenter for Molecular Genetics, Yamagata University, Yamagata, Japan.
Tomofumi MisakaDepartment of Cardiovascular Medicine, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Yusuke KimishimaDepartment of Cardiovascular Medicine, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Kento WadaDepartment of Cardiovascular Medicine, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Yusuke TomitaDepartment of Cardiovascular Medicine, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Saori MiuraDepartment of Blood Transfusion and Transplantation Immunology, School of Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Yuka SatoDepartment of Blood Transfusion and Transplantation Immunology, School of Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Kosaku MimuraDepartment of Blood Transfusion and Transplantation Immunology, School of Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Koichi SugimotoDepartment of Cardiovascular Medicine, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Kazuhiko NakazatoDepartment of Cardiovascular Medicine, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Kenneth E NolletDepartment of Blood Transfusion and Transplantation Immunology, School of Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Kazuei OgawaDepartment of Hematology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Takayuki IkezoeDepartment of Hematology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Yuko HashimotoDepartment of Diagnostic Pathology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Yasuchika TakeishiDepartment of Cardiovascular Medicine, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Kazuhiko IkedaDepartment of Blood Transfusion and Transplantation Immunology, School of Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan. kazu-ike@fmu.ac.jp.ORCID 0000-0002-5269-269X
Fukushima Medical University · JPYamagata University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Frameshifts in the Calreticulin (CALR) exon 9 provide a recurrent driver mutation of essential thrombocythemia (ET) and primary myelofibrosis among myeloproliferative neoplasms (MPNs). Here, we generated knock-in mice with murine Calr exon 9 mimicking the human CALR mutations, using the CRISPR-Cas9 method. Knock-in mice with del10 [Calr

Indexed as

AnimalsFrameshift MutationHumansHypertension, PulmonaryMiceMyeloproliferative DisordersCALREssential thrombocythemiaMacrophageMyeloproliferative neoplasmsPulmonary hypertension

Identifiers

PMID33785036
PMCPMC8011226
OpenAlexW3143759707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.